Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOX with continuous or intermittent cetuximab in first-line metastatic colorectal cancer
2005-000117-34Phase 3Completed
- Sponsor
- Nordic Colorectal Cancer Biomodulation Group
- Start
- Mar 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC) (3 arms), sponsored by Nordic Colorectal Cancer Biomodulation Group. Primary endpoint: Time to progression. Started Mar 2005; status: completed.
02
Drugs
cetuximaboxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2005-000117-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000117-34.